On Monday, May 4, 2026, the first Monday of the month, on the Met Gala carpet, Rihanna reached for Sheinelle Jones’ hand. She held eye contact. On video, in front of the cameras and the crowd and the step-and-repeat, she told Sheinelle: “You deserve to be poured into. And you’re beautiful, you’re a Black journalist, and I respect you. I love you for this.” That was the language. Not comforted. Not supported. Poured into. Sheinelle, working the carpet in her professional capacity for TODAY, had asked Rihanna how her night was going; the two spoke for a moment before Rihanna offered the line that would travel far past that carpet.

It was the opening week of what public health calendars call Brain Cancer Awareness Month May, marked by a gray ribbon and a scattering of hashtags most people will never see. Nineteen days after that carpet, the country would reach the one-year anniversary of Uche Ojeh’s death. The gray ribbons would come down at the end of the month. The scheduled tributes would stop. The awareness campaigns would file their reports and start planning next year.

Sheinelle Jones would still be a widow.

What Uche Was

Uche Ojeh was 45 years old when he died on May 23, 2025. He had been married to Sheinelle for seventeen years. They met at Northwestern University in the late 1990s and married in Philadelphia in September 2007. He was the father of their three children. According to the tributes NBC and TODAY published after his death, he was remembered as a devoted husband and loving father, full of joy and warmth present at the milestones that make up an ordinary, good life.

He died of glioblastoma. NBC and USA Today confirmed the cause of death when the news broke in May 2025. That word glioblastoma is the one this piece is about. Not because it is unusual. Because it is common enough to kill thousands of people in this country every year, including Uche Ojeh, and yet almost nobody outside the families who lose someone to it knows what it actually is.

What Glioblastoma Is

Glioblastoma is the most common malignant primary brain tumor in adults. In the World Health Organization’s classification of central nervous system tumors, it is a grade 4 diffuse astrocytic tumor the most aggressive tier of the grading system.

The current standard of care is the Stupp protocol: maximal safe surgical resection, followed by radiation with concurrent and adjuvant temozolomide, an oral chemotherapy agent. This has been the standard for roughly two decades, and it is what most patients receive when they can access it.

With that standard of care, median survival from diagnosis is approximately twelve to fifteen months, according to a 2025 clinical review published in the peer-reviewed literature. The Mayo Clinic reports that in large studies, approximately five to seven percent of glioblastoma patients are alive five years after diagnosis. Without treatment, survival is typically far shorter a matter of months, as described by major cancer centers and reflected in national coverage of cases like Uche’s.

Those numbers are not a footnote. They are the shape of what a glioblastoma diagnosis does to a family. Sheinelle has said publicly that she learned of Uche’s diagnosis a few weeks before running a marathon in 2023, and that she spent much of the time that followed convincing herself he would be okay. He died less than two years later.

The National Brain Tumor Society’s figures put annual U.S. glioblastoma diagnoses in the low tens of thousands, with a comparable annual death toll a scale that varies slightly by source and year, but the shape does not vary: this disease enters a family, moves fast, and leaves someone widowed.

Who Is Not in the Trials

A 2018 analysis published in Neuro-Oncology examined the glioblastoma clinical trials landscape and found that a minority of trials even reported the race or ethnicity of enrolled participants a gap that was especially pronounced in early-phase studies.

A 2020 study evaluating U.S. glioblastoma interventional trials from 1994 to 2019 concluded that trial participants did not fully represent the underlying glioblastoma patient population, with racial and ethnic minorities underrepresented. More recent work has documented related disparities: Black and Hispanic glioblastoma patients are less likely to receive guideline-concordant treatment, including radiation, systemic chemotherapy, and molecular diagnostic testing that increasingly guides precision care.

A 2023 study published in the Journal of Clinical Oncology found that in states where Medicaid both expanded coverage and paid for the routine costs of clinical trial participation, enrollment of Black and Hispanic participants increased modestly. Not dramatically. Not completely. Modestly, which is the word researchers use when a policy intervention moves the needle a little but does not close the gap.

This is not new information. It is documented in the peer-reviewed literature going back years, alongside a small but growing “equity-driven” movement inside neuro-oncology health equity roadmaps, working groups inside pediatric brain tumor consortia, and calls to build bias audits into AI-assisted diagnosis trying to translate that research into practice. For most families, none of that infrastructure is visible. What they see is delay, distance from specialized centers, and clinical trials that feel out of reach.

Whose Grief Gets a Ribbon

Brain Cancer Awareness Month is May. The gray ribbon is the symbol, and organizations like the Brain Tumour Foundation ask the public to “Turn May Grey” to light landmarks, share stories, and post about what isn’t visible in a brain tumor diagnosis. It is real advocacy work. It also has a start date and an end date.

The high-profile glioblastoma deaths that have received sustained national coverage in the past decade and a half include Beau Biden, John McCain, and Ted Kennedy. Their obituaries were long; their disease became a teachable moment for the whole country.

Uche Ojeh’s death was covered tothe TODAY show announced it, NBC ran a tribute, and USA Today and other national outlets carried the news. This was not an erasure in the way the word usually means. But it was a brief tribute tied to a celebrity co-host, not the start of an extended national conversation about glioblastoma in Black communities. There was no wave of explainer pieces about clinical trial disparities framed around his family’s loss.

This is the pattern MB tracks: not the absence of coverage, but the unevenness of what that coverage produces. Whose death becomes a teachable moment for a country, and whose death gets a segment.

What Rihanna Did

Which brings us back to the Met Gala carpet.

Sheinelle Jones did not attend the 2026 Met Gala to be poured into. She attended as a working journalist covering one of the largest cultural events of the year for her network. Her presence there was professional.

Rihanna’s gesture the hand-hold, the eye contact, the specific language of “pouring into”was an acknowledgment that the professional does not cancel the personal. That a widow eleven months into her loss is still a widow, even in couture, even nineteen days from an anniversary the world would not mark for her the way it marked Beau Biden’s or John McCain’s.

One Black woman, in front of every camera the fashion industry could point, said something specific to another Black woman about care. Not general. Specific. You deserve to be poured into. On the record. In the frame.

What Pouring Into Us Means

This series is called Pouring Into Us because Black women in this country are asked to carry more than the average person carries a labor pattern documented across workforce and caregiving research. MB’s editorial position is that we do not have to be poured into by systems, by the news cycle, or by an awareness calendar in order to keep going. What this series tracks is the moments when the pouring goes the other way when one of us does for another of us what the world will not.

Rihanna and Sheinelle at the 2026 Met Gala is one of those moments. It is not the reason Sheinelle will get through this year; she is getting through this year day by day, with the private support of family, faith, and the people who knew Uche and love her. What Rihanna did was publicly witness a thing that was already true.

But that public witness matters, because Brain Cancer Awareness Month will end on schedule, and a widow whose husband died of a disease that disproportionately lacks representation in the research shaping its own standard of care is still a widow nineteen days from her first anniversary of loss. Somebody chose to see her anyway. In couture. On the record. Loud enough for it to travel.

What This Piece Is Not

This piece is not a portrait of Sheinelle Jones’ grief. That belongs to her. She has spoken publicly, on her own terms, including in a September 2025 LA Times interview about how she has coped. What she has not said publicly, MB does not speculate about.

This piece is not a call to contact her, her family, or Rihanna’s team, or to produce engagement content about her. If MB’s readers want to honor Uche and Sheinelle, the way to do it is by learning what glioblastoma actually is, asking about clinical trial diversity in cancer research, and pouring into the Black women in their own lives carrying more than the world sees.

This piece is not a solved thing. Sheinelle is still a widow. Three children are still growing up without their father. The disparities in glioblastoma trials still exist. The next Brain Cancer Awareness Month will come and go. The next Met Gala will roll out a different carpet. One month closes. The anniversary arrives regardless. The widow remains. The pouring, when it comes, comes from us.

Sources

• NBC/TODAY tribute confirming Uche Ojeh’s age, marriage, children, and cause of death (glioblastoma), May 2025[today +1]

• USA Today report confirming Uche Ojeh’s death and glioblastoma diagnosis, May 2025[usatoday]

• LA Times interview with Sheinelle Jones on grief and coping, September 2025[latimes]

• People, E! News, TODAY, NJ.com, TVInsider, Oprah Daily coverage of the Rihanna–Sheinelle Met Gala 2026 exchange, May 2026[today +4]

• Vanity Fair, People, NBC New York, Town & Country: Met Gala 2026 held May 4, 2026[people +3]

• Mayo Clinic glioblastoma survival rates page (5–7% five-year survival)[mayoclinic]

• 2025 clinical review of glioblastoma standard of care (12–15 month median survival)[pmc.ncbi.nlm.nih]

• Ludmir et al., Neuro-Oncology, 2018: majority of glioblastoma trials do not report race/ethnicity[nih]

• 2020 glioblastoma trial enrollment study (1994–2019): racial/ethnic minorities underrepresented[nih]

• 2023 Journal of Clinical Oncology study: Medicaid trial-cost coverage modestly increased Black/Hispanic enrollment[ascopubs]

• Studies on racial disparities in glioblastoma treatment access and molecular testing[nih +2]

• AAN Roadmap to Neurologic Health Equity; PNOC Health Equity working group; equity-driven AI in neuro-oncology[pnoc +3]

• Brain Tumour Foundation of Canada, “Turn May Grey” 2026 press release[braintumour]